On June 8, DotBio-B (09606.HK) fell 5.25% in regular trading, trading at 176.5 HKD/share, with trading volume of approximately 53.62 million HKD. The stock had previously rebounded over 6% on June 5, driven by continuous share buybacks and ASCO clinical data catalysts, but the recovery proved unsustainable.

The company conducted buybacks on four consecutive trading days from June 2 to June 5, repurchasing a cumulative 145,600 shares for approximately 28.61 million HKD. On June 4, the board further proposed authorizing buybacks of up to 10% of outstanding shares. Despite these efforts, persistent selling pressure has overwhelmed the buyback support, with the stock declining over 17% from its June 1 levels.

At the 2026 ASCO annual meeting, DotBio's B7-H4 ADC candidate DB-1312/BG-C9074, licensed to BeiGene, presented promising Phase 1a data via rapid oral presentation, demonstrating favorable safety and preliminary efficacy in advanced solid tumors. However, the positive clinical readout has failed to translate into sustained share price support amid broader sector weakness and investor concerns over the company's cash position.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)